MIL95

MIL95 is an anti-CD47 monoclonal antibody that we jointly developed with Keymed (stock code: 02162.HK) for the treatment of lymphoma and advanced solid tumors. 

In preclinical studies, MIL95 demonstrates high binding affinity, strong blocking activity against CD47 and SIRP interaction, and potent anti-tumor activity. Moreover, MIL95 did not induce erythrocyte agglutination, suggesting a favorable safety profile.

MIL95 is currently under Phase I clinical trial in China.